Alexandria Venture Investments has taken part in a series B round for the cytokine immunotherapy developer following a $35m series A.
Bright Peak Therapeutics, a Switzerland-based cancer and autoimmune disease drug developer, has received $107m in series B funding from investors including life sciences real estate investment trust Alexandria Real Estate Equities.
Investment manager RA Capital Management led the round, which was also backed by financial services and investment group Fidelity, sovereign wealth fund Qatar Investment Authority, Versant Ventures, Invus, and an unspecified healthcare investment fund and funds and accounts managed by BlackRock.
Alexandria Real Estate Equities was represented in the…
